An Oregon State Public Interest Research Group report says that on the average, Oregonians spent 10 times more for 20 brand-name treatments whose generics were delayed by patent settlements. "Intellectual property, and the ability to manage patent litigation, is critical to research-intensive biopharmaceutical companies," PhRMA general counsel Mit Spears said

Related Summaries